research The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
Search
forProducts matching "increased prostate cancer risk"
Tracking 1 products like 14 Topical Finasteride & Minoxidil Spray from by companies like Hims. View product »
Sort by
Research
60-90 / 1000+ results 
research Allelic frequencies for the seventeen Y-STR loci observed in Iraqi male patients with prostate cancer
Certain genetic markers on the Y-chromosome may influence prostate cancer risk in Iraqi males.
research Effects of lifelong testosterone exposure on health and disease using Mendelian randomization
Higher testosterone levels can increase the risk of certain diseases like type 2 diabetes in women and prostate cancer in men, but can also protect against autoimmune diseases and hair loss. It also affects body fat and bone density.
research Relation of urinary stone disease with androgenetic alopecia and serum testosterone levels
Balding and low testosterone increase risk of urinary stones.
research Finasteride: Middle-Age Cure-All for Alopecia and Benign Prostatic Hyperplasia?
Finasteride reduces prostate cancer risk but may increase high-grade cancer cases.
research Decision letter: Effects of lifelong testosterone exposure on health and disease using Mendelian randomization
Increased free testosterone can lead to stronger bones and less body fat but also higher risks of prostate cancer, hair loss, spine issues, and high blood pressure.
research Latent hazard in PC and BPH patients referred to antiandrogens:PC aggressiveness and NE differentiation
Long-term antiandrogen use may increase aggressive prostate cancer risk.
research Propecia: The Goose That Lays the Golden Eggs
Finasteride is popular for treating male hair loss but may increase the risk of serious prostate cancer and has other potential side effects.
research MP11-05 THE UROLOGIC IMPACT OF LONG-TERM FINASTERIDE-1 MG USE FOR ANDROGENIC ALOPECIA: A MATCHED-COHORT DATABASE ANALYSIS
Long-term finasteride use may lower prostate cancer risk but increase the need for erectile dysfunction medication.
research Level-1 Data From the REDUCE Study and the PCPT Data
Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.
research Clinical benefits and adverse effects of genetically-elevated free testosterone levels: a Mendelian randomization analysis
Higher free testosterone levels can increase bone density and decrease body fat but may raise the risk of prostate cancer, hair loss, and benign prostate enlargement.
research Alopecia: the case for medical necessity.
Alopecia should be treated as a medical condition because it may increase the risk of serious diseases and psychological issues.
research Association between male pattern baldness and prostate disease: A meta-analysis
Men with male pattern baldness have a higher risk of aggressive prostate cancer and benign prostatic hyperplasia.
research Implicações da toma crónica da Finasteride para a Alopécia Androgenética no Carcinoma da Próstata
Finasteride can reduce prostate cancer risk but may delay diagnosis and cause sexual side effects.
research Guidelines on the use of finasteride in androgenetic alopecia
Taking 1 mg of finasteride daily can increase hair count and improve hair appearance, but it may have side effects on sexual function and a potential risk of prostate cancer. It may not be effective for postmenopausal women unless taken in higher doses.
research Author response: Effects of lifelong testosterone exposure on health and disease using Mendelian randomization
Long-term high testosterone levels can improve bone density and reduce body fat but may increase the risk of prostate cancer and high blood pressure.
research Finasteride
Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.
research Prostate Carcinoma, what would be the best to do ?
Correct testosterone levels for age to treat prostate cancer, using low dose treatments as necessary.
research 1449 PROSTATE CANCER PATIENTS WITH METABOLIC SYNDROME SHOWED LOW GRADE GLEASON SCORE WHEN DIAGNOSED ON BIOPSY
Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.
research Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer
Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.
research A powerful method for pleiotropic analysis under composite null hypothesis identifies novel shared loci between Type 2 Diabetes and Prostate Cancer
New method finds genetic links between Type 2 Diabetes and Prostate Cancer not seen before.
research Prostate cancer and androgenic alopecia
The document suggests more research is needed to understand the link between baldness and prostate cancer.
research Understanding the Epidemiology, Natural History, and Key Pathways Involved in Prostate Cancer
Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.
research Gleason grading controversies: what the chemoprevention trials have taught us
Finasteride reduces prostate cancer risk by 30% without affecting Gleason scores.
research News in brief
Breast cancer survivors may have a higher risk of falls, tamoxifen could prevent breast cancer and deaths, new guidelines urge caution with prostate cancer therapy, and early balding in men may indicate a higher prostate cancer risk.
research Off-label prescriptions: patient safety first
Off-label drug use can be risky and requires careful consideration to ensure patient safety.
research Finasteride: Middle-Age Cure-All for Alopecia and Benign Prostatic Hyperplasia?–Reply–II
Finasteride is beneficial for BPH but requires careful monitoring due to cancer risks.
research Significance of the polyglutamine tract polymorphism in the androgen receptor
The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.
research Regarding prostate-specific antigen: let's not shoot the messenger
The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.
research Study Answers Some Questions about Androgen Suppression Pre-Radiation, but Not All
Extending androgen suppression before radiotherapy offers no extra survival benefit for intermediate-risk prostate cancer.